| HAS [Haute Autorité de Santé – French National Authority for Health] contribution. | 风湿性
> 轴性脊柱关节炎 | 监管合作伙伴关系
> 与监管机构合作 | 1,000 | National | Sometimes | 114996619378 |
| Patient contribution to the HAS [Haute Autorité de Santé – French National Authority for Health]. | 癌症
> 癌症：血液 | 监管合作伙伴关系
> 与监管机构合作 | 100 | National | Sometimes | 114997550596 |
| Contributions during the evaluation of a new treatment. | 癌症
> 癌症：罕见 | 监管合作伙伴关系
> 与监管机构合作 | 1,000 | National | Rarely | 115021537282 |
| Submissions to the HAS [Haute Autorité de Santé – French National Authority for Health] and exchanges with the ANSM [Agence nationale de sécurité du médicament et des produits de santé – National Agency for the Safety of Medicines and Health Products]. | 稀有
> 罕见病：呼吸系统 | 监管合作伙伴关系
> 与监管机构合作 | 1,000 | National | Regularly | 115037393435 |
| Engagement with HAS [Haute Autorité de Santé – French National Authority for Health]. | 癌症
> 癌症：血液 | 监管合作伙伴关系
> 与监管机构合作 | 100,000 | National | Regularly | 115058165499 |
| ANSM [Agence nationale de sécurité du médicament et des produits de santé – National Agency for the Safety of Medicines and Health Products], the European Commission. | 稀有
> 罕见病：代谢/溶酶体 | 监管合作伙伴关系
> 与监管机构合作 | 5,000 | National | Sometimes | 119024758732 |
| Contributions submitted to the HAS [Haute Autorité de Santé – French National Authority for Health]. | 癌症
> 癌症：血液 | 监管合作伙伴关系
> 参与卫生技术评估（HTA）和报销审查 | 100,000 | National | Regularly | 114996624570 |
| ANSM [Agence nationale de sécurité du médicament et des produits de santé – National Agency for the Safety of Medicines and Health Products] sets the reimbursement rates for medicines. | 神经系统
> 神经系统：其他 | 监管合作伙伴关系
> 参与卫生技术评估（HTA）和报销审查 | 1,000 | National | Sometimes | 114996998287 |
| HAS [Haute Autorité de Santé – French National Authority for Health] consultations. | 稀有
> 罕见病：大多数类型 | 监管合作伙伴关系
> 参与卫生技术评估（HTA）和报销审查 | 1,000 | National | Sometimes | 114997498340 |
| ANSM [Agence nationale de sécurité du médicament et des produits de santé – National Agency for Medicines and Health Products Safety], HAS [Haute Autorité de Santé – French National Authority for Health]. | 神经退行性
> 帕金森病 | 监管合作伙伴关系
> 参与卫生技术评估（HTA）和报销审查 | 100,000 | National | Sometimes | 115006691512 |
| HAS [Haute Autorité de Santé – French National Authority for Health] dossier submission for reimbursement. | 稀有
> 罕见病：遗传性 | 监管合作伙伴关系
> 参与卫生技术评估（HTA）和报销审查 | 100 | National | Sometimes | 115007035544 |
| Our national organisation is frequently consulted by the HAS [Haute Autorité de Santé – French National Authority for Health] and the CEPS [Comité Économique des Produits de Santé – Economic Committee for Health Products]. At the regional level, we contribute through concrete examples. | 稀有
> 罕见病：大多数类型 | 监管合作伙伴关系
> 参与卫生技术评估（HTA）和报销审查 | 1,000 | Regional | Rarely | 115019695255 |
| HAS [Haute Autorité de Santé – French National Authority for Health]. | 癌症
> 癌症：肺 | 监管合作伙伴关系
> 参与卫生技术评估（HTA）和报销审查 | 100 | National | Sometimes | 115023193878 |
| HAS [Haute Autorité de Santé – French National Authority for Health]. | 风湿性
> 风湿性疾病：大多数类型 | 监管合作伙伴关系
> 参与卫生技术评估（HTA）和报销审查 | 100,000 | National | Regularly | 115028340764 |
| Submissions to the HAS [Haute Autorité de Santé – French National Authority for Health] and exchanges with the ANSM [Agence nationale de sécurité du médicament et des produits de santé – National Agency for the Safety of Medicines and Health Products]. | 稀有
> 罕见病：呼吸系统 | 监管合作伙伴关系
> 参与卫生技术评估（HTA）和报销审查 | 1,000 | National | Regularly | 115037393435 |
| HAS [Haute Autorité de Santé – French National Authority for Health], ANSM [Agence nationale de sécurité du médicament et des produits de santé – National Agency for the Safety of Medicines and Health Products], DGOS [Direction générale de l'offre de soins – Directorate General for Health Care Provision]. | 稀有
> 罕见病：贫血症 | 监管合作伙伴关系
> 参与卫生技术评估（HTA）和报销审查 | 1,000 | National | Regularly | 115051867960 |
| Engagement with HAS [Haute Autorité de Santé – French National Authority for Health]. | 癌症
> 癌症：血液 | 监管合作伙伴关系
> 参与卫生技术评估（HTA）和报销审查 | 100,000 | National | Regularly | 115058165499 |
| HAS [Haute Autorité de Santé – French National Authority for Health], contributions to the AMM [autorisation de mise sur le marché – marketing authorisation] processes for new medicines. | 出血
> 出血性疾病：其他 | 监管合作伙伴关系
> 为营销授权申报做出贡献 | 1,000 | National | Regularly | 114998547552 |
| Opinions on new medicines prior to AMM [Autorisation de Mise sur le Marché – Marketing Authorisation]. | 患者安全
> 医源性 | 监管合作伙伴关系
> 为营销授权申报做出贡献 | 1,000 | National | Regularly | 115006692431 |
| HAS [Haute Autorité de Santé – French National Authority for Health] contributions in support of AMM [Autorisation de Mise sur le Marché – Marketing Authorisation] applications. | 神经肌肉
> 重症肌无力 | 监管合作伙伴关系
> 为营销授权申报做出贡献 | Do not know | International | Regularly | 115019651354 |
| Apprenticeship programme at the ANSM [Agence nationale de sécurité du médicament et des produits de santé – National Agency for the Safety of Medicines and Health Products], contributing to the evaluation of medicinal products. | 内分泌
> 生长障碍 | 监管合作伙伴关系
> 为营销授权申报做出贡献 | 1,000 | International | Regularly | 115043122988 |
| Participation in fast-track designations for clinical trials, inclusion of adolescents, the Biotech Act, and related initiatives. | 癌症
> 癌症：儿童/青少年 | 监管合作伙伴关系
> 为营销授权申报做出贡献 | 1,000 | International | Regularly | 115053274069 |
| ANSM [Agence nationale de sécurité du médicament et des produits de santé – National Agency for the Safety of Medicines and Health Products]. | 心血管
> 心血管：大多数类型 | 监管合作伙伴关系
> 为营销授权申报做出贡献 | 1,000 | National | Regularly | 115057828483 |
| Our national organisation is frequently consulted by the HAS [Haute Autorité de Santé – French National Authority for Health] and the CEPS [Comité Économique des Produits de Santé – Economic Committee for Health Products]. At the regional level, we contribute through concrete examples. | 稀有
> 罕见病：大多数类型 | 监管合作伙伴关系
> 参加/主持与政策制定者/监管机构的会议 | 1,000 | Regional | Rarely | 115019695255 |
| Consultation with the Ministry of Health. | 癌症
> 癌症：乳腺癌 | 监管合作伙伴关系
> 参加/主持与政策制定者/监管机构的会议 | 10,000 | National | Rarely | 115037385316 |
| Apprenticeship programme at the ANSM [Agence nationale de sécurité du médicament et des produits de santé – National Agency for the Safety of Medicines and Health Products], contributing to the evaluation of medicinal products. | 内分泌
> 生长障碍 | 监管合作伙伴关系
> 参加/主持与政策制定者/监管机构的会议 | 1,000 | International | Regularly | 115043122988 |
| Engagement with members of parliament, the Ministry of Health, and the HAS [Haute Autorité de Santé – French National Authority for Health]; advocacy efforts to remove genomic tests from the RIHN [Référentiel des actes Innovants Hors Nomenclature – Reference Framework for Innovative Acts Outside the Nomenclature]; presentations at congresses and seminars; and chairing of symposia. | 癌症
> 癌症：乳腺癌 | 监管合作伙伴关系
> 参加/主持与政策制定者/监管机构的会议 | 10,000 | National | Regularly | 115049335124 |
| Participation in fast-track designations for clinical trials, inclusion of adolescents, the Biotech Act [at EU level], and related initiatives. | 癌症
> 癌症：儿童/青少年 | 影响政策和立法
> 影响医疗保健政策和立法 | 1,000 | International | Regularly | 115053274069 |
| Engagement with members of parliament, the Ministry of Health, and the HAS [Haute Autorité de Santé – French National Authority for Health]; advocacy efforts to remove genomic tests from the RIHN [Référentiel des actes Innovants Hors Nomenclature – Reference Framework for Innovative Acts Outside the Nomenclature]; presentations at congresses and seminars; and chairing of symposia. | 癌症
> 癌症：乳腺癌 | 影响政策和立法
> 动员议员和政治领导人 | 10,000 | National | Regularly | 115049335124 |
| Regarding the reimbursement of growth hormone in 2012. | 稀有
> 罕见病：遗传性 | 定价与可负担性倡导
> 倡导公平的药品定价 | 100 | National | Sometimes | 114999124203 |
| Legislation on patient out-of-pocket costs. | 癌症
> 癌症：乳腺癌 | 定价与可负担性倡导
> 倡导公平的药品定价 | 1,000 | National | Regularly | 115028639358 |
| ANSM [Agence nationale de sécurité du médicament et des produits de santé – National Agency for the Safety of Medicines and Health Products] sets the reimbursement rates for medicines. | 神经系统
> 神经系统：其他 | 定价与可负担性倡导
> 参与价格审查委员会谈判 | 1,000 | National | Sometimes | 114996998287 |
| Legislation on patient out-of-pocket costs. | 癌症
> 癌症：乳腺癌 | 定价与可负担性倡导
> 解决低收入和弱势群体面临的费用障碍 | 1,000 | National | Regularly | 115028639358 |
| Reimbursement of growth hormone. | 总体健康
> 总体健康 | 定价与可负担性倡导
> 倡导将产品纳入报销目录/国家处方集 | 100 | National | Sometimes | 114996944911 |
| Regarding the reimbursement of growth hormone in 2012. | 稀有
> 罕见病：遗传性 | 定价与可负担性倡导
> 倡导将产品纳入报销目录/国家处方集 | 100 | National | Sometimes | 114999124203 |
| Advocacy efforts to remove genomic tests from the RIHN [Référentiel des actes Innovants Hors Nomenclature – Reference Framework for Innovative Acts Outside the Nomenclature] [The issue centers on genomic signature tests used in early-stage hormone receptor–positive, HER2-negative breast cancer, to determine whether adjuvant chemotherapy is likely to provide meaningful benefit. The logic is that this should allow many women to avoid unnecessary chemotherapy. However, the French breast-cancer patient groups argue that under the RIHN scheme elligible patients find it difficult to access the genomic tests. They want the genomic tests to be made available through the general social-security system.] | 癌症
> 癌症：乳腺癌 | 定价与可负担性倡导
> 倡导将产品纳入报销目录/国家处方集 | 10,000 | National | Regularly | 115049335124 |
| Correspondence submitted to request reimbursement of a specific voice prosthesis. | 残疾
> 残疾：其他 | 改善访问路径
> 促进公平获取药品/医疗保健 | 1,000 | National | Rarely | 115012114375 |
| Hybrid closed-loop systems, new CGM [Continuous Glucose Monitoring] devices. | 内分泌
> 糖尿病（1型和2型） | 改善访问路径
> 促进公平获取药品/医疗保健 | 100 | Regional | Regularly | 115028487590 |
| The HAS [Haute Autorité de Santé – French National Authority for Health] should facilitate access to innovative medicines that hold a temporary authorisation. | 癌症
> 癌症：血液 | 改善访问路径
> 促进公平获取药品/医疗保健 | 1,000 | National | Regularly | 115051136978 |
| Patient advisory council for scientific studies. | 总体健康
> 肥胖症 | 循证患者意见
> 利用患者洞察来指导决策 | 1,000 | International | Regularly | 115028400081 |
| Patient contributions to the HAS [Haute Autorité de Santé – French National Authority for Health]. | 癌症
> 癌症：血液 | 循证患者意见
> 利用患者故事和亲身经历叙述 | 100 | National | Sometimes | 114997550596 |
| Our national organisation is frequently consulted by the HAS [Haute Autorité de Santé – French National Authority for Health] and the CEPS [Comité Économique des Produits de Santé – Economic Committee for Health Products]. At the regional level, we contribute through concrete examples. | 稀有
> 罕见病：大多数类型 | 循证患者意见
> 利用患者故事和亲身经历叙述 | 1,000 | Regional | Rarely | 115019695255 |
| Clinical trials, opinion videos. | 内分泌
> 糖尿病（1型和2型） | 循证患者意见
> 利用患者故事和亲身经历叙述 | 100,000 | National | Sometimes | 115049743006 |
| Patient rights and contributing our experience as patients. | 心血管
> 心血管：大多数类型 | 循证患者意见
> 利用患者故事和亲身经历叙述 | 100 | Regional | Regularly | 115060504774 |
| Questionnaire for input from patient and user associations. | 心血管
> 家族性高胆固醇血症（FH） | 循证患者意见
> 开展调查/研究以生成数据 | 1,000 | National | Sometimes | 115053041303 |
| Patient advisory council for scientific studies. | 总体健康
> 肥胖症 | 诊断与药品配送
> 协作设计临床试验 | 1,000 | International | Regularly | 115028400081 |
| Clinical trials. | 内分泌
> 糖尿病（1型和2型） | 诊断与药品配送
> 协作设计临床试验 | 100,000 | National | Sometimes | 115049743006 |
| Participation in fast-track designations for clinical trials, inclusion of adolescents, the Biotech Act, and related initiatives. | 癌症
> 癌症：儿童/青少年 | 诊断与药品配送
> 协作设计临床试验 | 1,000 | International | Regularly | 115053274069 |
| The Fédération Française des Groupements de Parkinsoniens [French Federation of Parkinson's Patient Groups] represents Parkinson's patients in health governance bodies and ministerial forums. | 神经退行性
> 帕金森病 | 机构治理
> 确保在政府咨询机构中的代表性 | 1,000 | National | Regularly | 114997021296 |
| ANRS [Agence nationale de recherches sur le sida et les hépatites virales – National Agency for Research on AIDS and Viral Hepatitis], Coress [Coordination régionale en santé sexuelle - Regional Coordination for Sexual Health]. | HIV
> HIV和肝炎 | 机构治理
> 在多利益相关方网络中高效协作 | 1,000 | National | Regularly | 115035724756 |
| Advocacy, discrimination. | 风湿性
> 银屑病和银屑病关节炎 | 维护患者权益/提高生活质量
> 保护/改善患者体验 | 100,000 | National | Regularly | 115042996062 |
| Patient rights and contributing our experience as patients. | 心血管
> 心血管：大多数类型 | 维护患者权益/提高生活质量
> 保护/改善患者体验 | 100 | Regional | Regularly | 115060504774 |
互动
行动与倡导
27 提及
